Phase 2 Endometrial Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have been newly diagnosed (not yet treated) with cervical cancer confirmed by a laboratory test, at a specific advanced stage (FIGO 2018 Stage IB3, II, IIIA–IIIC1 with a tumour 6cm or larger, Stage IVA, or Stage IVB), where the cancer has not spread so extensively that urgent systemic treatment is needed right away
- People whose cervical cancer is one of these tissue types: squamous cell carcinoma, adenosquamous carcinoma, or adenocarcinoma
- People whose kidneys, liver, bone marrow, and other organs are functioning well enough to tolerate treatment (confirm with trial site)
- People who are reasonably active and able to carry out daily activities, as measured by a standard medical scoring system called the Gynecologic Oncology Group performance status of 0, 1, or 2 (confirm with trial site)
- People of childbearing potential who agree to use two forms of contraception during the trial
- People who are able to understand the trial information and are willing to sign a written consent form
Who may not be able to join:
- People who currently have another active invasive cancer at the same time
- People who have been diagnosed with another invasive cancer within the last three years (exceptions may apply for non-melanoma skin cancer or a previous non-invasive cervical cancer — confirm with trial site)
- People who have previously had radiation therapy to the pelvis in a way that would cause the total radiation dose to exceed safe limits for surrounding healthy tissue, as judged by the treating doctor
- People who are currently taking part in another clinical trial involving an experimental cancer treatment
- People with a known history of serious allergic reactions to cisplatin or to other drugs that are chemically or biologically similar to those used in this trial
- People who have an uncontrolled ongoing illness, as determined by the treating doctor
- People who are pregnant or breastfeeding
- People with a known history or current signs of heart disease, or who have previously been treated with medications that can affect the heart, and whose heart function is assessed as being below a certain level (Class 2B or worse on the New York Heart Association scale — confirm with trial site)
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Denise Fabian, MD, University of Kentucky
Phone: 859-323-2354
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
MRI assessed rate of complete response
Can't join this trial?
Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.